Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”

    Carlos Gustavo Wambier, Sergio Vano-Galvan, John D. McCoy, Alba Gómez-Zubiaur, Sabina Herrera, Ángela Hermosa-Gelbard, Oscar M. Moreno-Arrones, N. Jiménez-Gómez, Álvaro González-Cantero, Pablo Fonda-Pascual, Gonzalo Segurado-Miravalles, Jerry Shapiro, B. Pérez-García, Andy Goren
    TLDR Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
    The document titled "Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The 'Gabrin sign'" presents evidence that suggests a link between androgen sensitivity and severe symptoms of COVID-19. The study examined 175 individuals with confirmed COVID-19 who were admitted to hospitals in Madrid, Spain. The study found that 67% of the patients had androgenetic alopecia, with a higher frequency in men than women. The study suggests that larger studies should be conducted to validate the association between androgen sensitivity and COVID-19 severity. The study also proposes the use of the term "Gabrin sign" to visually identify patients at higher risk for severe symptoms after COVID-19 infection. However, the study acknowledges limitations such as the small sample size and lack of a control group.
    View this study on jaad.org →

    Cited in this study